FZRQ — Immune Pharmaceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -307.81% | ||
| Return on Equity | -5114.63% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The Company’s oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Directors
- Adeel Ahmed-Daudpota PRE (34)
- Devin Shaw CFO (34)
- John Clark CTR
- Anthony Fiorino DRC
- Daniel Teper DRC (55)
- John Neczesny IND
- Jeffrey Paley IND (49)
- Last Annual
- December 31st, 2017
- Last Interim
- September 30th, 2018
- Incorporated
- March 9th, 1993
- Public Since
- September 19th, 2011
- No. of Shareholders
- 82
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Munich Stock Exchange
- Shares in Issue
- 172,878,093
- Address
- 1 Bridge Plaza N, Suite 270, FORT LEE, 07024
- Web
- Phone
- +1 2014642677
- Auditors
- BDO USA, LLP
Similar to FZRQ
Darwin AG
Munich Stock Exchange
FAQ
As of Today at 19:11 UTC, shares in Immune Pharmaceuticals are trading at €0.00. This share price information is delayed by 15 minutes.
Shares in Immune Pharmaceuticals last closed at €0.00 and the price had moved by -68.75% over the past 365 days. In terms of relative price strength the Immune Pharmaceuticals share price has underperformed the FTSE Global All Cap Index by -71.37% over the past year.
The overall consensus recommendation for Immune Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Immune Pharmaceuticals does not currently pay a dividend.
Immune Pharmaceuticals does not currently pay a dividend.
Immune Pharmaceuticals does not currently pay a dividend.
To buy shares in Immune Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.00, shares in Immune Pharmaceuticals had a market capitalisation of .
Here are the trading details for Immune Pharmaceuticals:
- Country of listing: Germany
- Exchange: MUN
- Ticker Symbol: FZRQ
Based on an overall assessment of its quality, value and momentum Immune Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immune Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -72.94%.
As of the last closing price of €0.00, shares in Immune Pharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immune Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immune Pharmaceuticals' management team is headed by:
- Adeel Ahmed-Daudpota - PRE
- Devin Shaw - CFO
- John Clark - CTR
- Anthony Fiorino - DRC
- Daniel Teper - DRC
- John Neczesny - IND
- Jeffrey Paley - IND